Shopping Cart
Your Cart is Empty
Quantity:
Subtotal
Taxes
Shipping
Total
There was an error with PayPalClick here to try again

News from CaSfA's Director
News from CaSfA's Director
Blog
16th Annual Prostate Cancer Symposium
Posted on May 20, 2013 at 4:20 PM |
I attended the Annual Massachusetts Prostate Cancer Symposium on Friday, May 17. I listened to some great lectures. Especially interesting were the talks about PSA (prostate-specific antigen) testing. This blood test started being used in the mid 1990's. Since it's use began, we have seen a doubling in the rate of prostate cancer, but not much change in the number of men dying from the disease. Many have taken a closer look at the PSA screening test and prostate cancer as a whole. It has been discovered that many cases of prostate cancer follow a slowly progressive course and men may even remain asymptomatic throughout their lifetime. For these men, the complications from treatment of prostate cancer outweigh any benefit of treatment. So, last year the US Preventative Services Task Force released this recommendation: "The reduction
in prostate cancer mortality 10 to 14 years after PSA-based screening is, at most,
very small, even for men in the optimal age range of 55 to 69 years. The harms
of screening include pain, fever, bleeding, infection, and transient urinary
difficulties associated with prostate biopsy,
psychological harm of false-positive test results, and overdiagnosis. Harms of
treatment include erectile dysfunction, urinary incontinence, bowel
dysfunction, and a small risk for premature death. Because of
the current inability to reliably distinguish tumors that will remain indolent
from those destined to be lethal, many men
are being subjected to the harms of treatment for prostate cancer that will
never become symptomatic. The benefits of PSA-based screening for prostate
cancer do not outweigh the harms." We need to determine which men are a risk for aggressive prostate cancer because these are the men who are dying from this cancer. We do know there are certain genetic mutations which are important (BRCA for example). Men who have any relatives with prostate cancer may choose to have a PSA test, or one of the newer (PCA-3) urinary screens. All men need to have a discussion with their physicians to determine their individual risk for prostate cancer and whether screening will be of benefit. |
Categories: prostate cancer
Post a Comment
Oops!
The words you entered did not match the given text. Please try again.
0 Comments
Loading...
/
Oops!
Oops, you forgot something.